<DOC>
	<DOCNO>NCT01781637</DOCNO>
	<brief_summary>The investigator perform double blind , placebo control clinical trial Xolair ( omalizumab ) four center safely rapidly desensitize patient severe peanut allergy . The investigator determine pretreatment anti-IgE mAb ( Xolair/omalizumab ) greatly reduce allergic reaction allow fast safe desensitization .</brief_summary>
	<brief_title>Peanut Reactivity Reduced Oral Tolerance Anti-IgE Clinical Trial</brief_title>
	<detailed_description>36 subject receive Xolair , 8 subject receive placebo . The study occur 4 site : Boston Children 's Hospital , Children 's Hospital Philadelphia , Stanford University Lurie Children 's Hospital . Patients pre-treated Xolair placebo rapid oral peanut desensitization . Patients continue receive Xolair 8 subsequent week desensitization , receive final dose Xolair one week reach high tolerate dose peanut .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Food Hypersensitivity</mesh_term>
	<mesh_term>Peanut Hypersensitivity</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Moderate severe peanut allergysensitive subject age 7 25 year old . Sensitivity peanut allergen document positive skin prick test result ( 6 mm diameter wheal great ) ImmunoCAP IgE level peanut &gt; 10 kU/L . Sensitivity peanut allergen base doubleblind placebocontrolled oral food challenge ( DBPCFC ) maximum cumulative 175 mg peanut protein dose . Subjects total IgE screening &lt; 50 kU/L &gt; 2,000 kU/L . Positive reaction placebo DBPCFC . Previous reaction omalizumab . Subjects history severe anaphylaxis peanut require intubation admission ICU , frequent allergic nonallergic urticaria , history consistent poorly control persistent asthma , gastrointestinal gastroesophageal disease .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Xolair</keyword>
	<keyword>omalizumab</keyword>
	<keyword>peanut</keyword>
	<keyword>oral desensitization</keyword>
</DOC>